Status:
SUSPENDED
Semaglutide to Reduce Atrial Fibrillation Burden
Lead Sponsor:
San Francisco Veterans Affairs Medical Center
Conditions:
Atrial Fibrillation
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Atrial fibrillation (AF) is the most common arrhythmia worldwide. AF is associated with obesity and the co-morbidities of obesity, including hypertension and obstructive sleep apnea (OSA) which increa...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years old with a BMI ≥ 27 kg/m2 who have paroxysmal AF with a ≥ 10% burden on ambulatory monitoring or a previous electrical cardioversion or early persistent AF (≥ 7 days, \< 3 months) who are willing to attempt rhythm control.
Exclusion
- Unable to consent
- A personal or family history of medullary thyroid carcinoma
- A personal or family history of multiple endocrine neoplasia syndrome type 2
- History of allergic reaction to Semaglutide or any of its components
- Currently pregnant or planning to become pregnant
- Currently breastfeeding
- History of acute pancreatitis
- History of pancreatic adenocarcinoma
- Previous or current GLP-1 RA use
- Previous or current use of alternative pharmacologic weight loss agents (phentermine, diethylpropion, orlistat, phentermine-topiramate, bupropion- naltrexone, gelesis100, or setmelanotide)
- Unable to tolerate anticoagulation
- History of bariatric surgery
Key Trial Info
Start Date :
May 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2028
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT05209165
Start Date
May 1 2023
End Date
May 1 2028
Last Update
October 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Veterans Affairs Medical Center San Francisco
San Francisco, California, United States, 94121